Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
McMaster Centre for Transfusion Research, Hamilton, Ontario, Canada.
J Thromb Haemost. 2019 May;17(5):787-794. doi: 10.1111/jth.14419. Epub 2019 Mar 20.
Essentials The diagnosis of ITP is based on a platelet count < 100 × 10 L and exclusion of other causes. There are no standard tests or biomarkers to diagnose ITP. The sensitivity of platelet autoantibody testing is low (53%). The specificity is high (> 90%). A positive autoantibody test can be useful to rule in ITP but a negative does not rule out ITP. SUMMARY: Background Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and an increased risk of bleeding. The sensitivity and specificity of platelet autoantibody tests is variable and their utility is uncertain. Objective The purpose of this study was to perform a systematic review and meta-analysis of platelet autoantibody tests in the diagnosis of ITP. Methods Ovid Medline, PubMed, and Web of Science were searched from inception until 31 May 2018. Two reviewers independently assessed studies for eligibility and extracted data. Studies that reported testing results for antiplatelet autoantibodies on platelets (direct tests) or in plasma/serum (indirect tests) for 20 or more ITP patients were included. Results Pooled estimates for sensitivity and specificity were calculated using a random effects model. Pooled estimates for the sensitivity and specificity of direct anti-platelet autoantibody testing for either anti-glycoprotein IIbIIIa or anti-glycoprotein IbIX were 53% (95% confidence interval [CI], 44-61%) and 93% (95% CI, 81-99%), respectively. For indirect testing, the pooled estimates for the sensitivity and specificity were 18% (95% CI, 12-24%) and 96% (95% CI, 87-100%), respectively. Conclusions Autoantibody testing in ITP patients has a high specificity but low sensitivity. A positive autoantibody test can be useful for ruling in ITP, but a negative test does not rule out ITP.
原发性免疫性血小板减少症的诊断基于血小板计数<100×10 9/L 和排除其他原因。目前没有标准的检查或生物标志物用于诊断 ITP。血小板自身抗体检测的敏感性较低(53%),特异性较高(>90%)。自身抗体检测阳性有助于诊断 ITP,但阴性不能排除 ITP。
免疫性血小板减少症(ITP)是一种自身免疫性疾病,其特征为血小板计数低,出血风险增加。血小板自身抗体检测的敏感性和特异性各不相同,其应用价值尚不确定。
本研究旨在对血小板自身抗体检测在 ITP 诊断中的应用进行系统评价和荟萃分析。
检索 Ovid Medline、PubMed 和 Web of Science 数据库,检索时间截至 2018 年 5 月 31 日。两名评审员独立评估研究的纳入和排除标准并提取数据。纳入研究需报告 20 例以上 ITP 患者的血小板(直接检测)或血浆/血清(间接检测)中抗血小板自身抗体的检测结果。
采用随机效应模型计算敏感性和特异性的汇总估计值。直接抗血小板自身抗体检测(抗糖蛋白 IIbIIIa 或抗糖蛋白 IbIX)的敏感性和特异性的汇总估计值分别为 53%(95%CI,44-61%)和 93%(95%CI,81-99%)。间接检测的敏感性和特异性汇总估计值分别为 18%(95%CI,12-24%)和 96%(95%CI,87-100%)。
ITP 患者的自身抗体检测特异性高,但敏感性低。自身抗体检测阳性有助于诊断 ITP,但阴性不能排除 ITP。